|Day Low/High||7.80 / 7.99|
|52 Wk Low/High||4.39 / 7.99|
We continue to screen new names amid a week of volatility in the broader market.
We added one new name to the Bullpen during a holiday-shortened week that ended with the worst daily decline since late June.
The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.
We added to two portfolio positions this week and also used market strength to book some profits.
Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BNS, GILT, HLIT, KRO, NCS, NQ, OSUR, TNGO Downgrades: CSC, FRED, ISLE, ZOES Initiations: RVEN Read on to get TheStreet Quant Ratings' detailed report:
OraSure (OSUR) stock rating was boosted to 'overweight' from 'equal weight' at Stephens on Monday.
Human Longevity Inc. Study on OMNIgene®¿ GUT Recently Published in Scientific Reports
In a largely quiet week for the market, we exited one position and trimmed 2 others, booking profits in each case.
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 433,773 share decrease in total short interest for OraSure Technologies Inc. , to 1,748,254, a decrease of 19.88% since 07/29/2016.
With a new Zika case now confirmed on Florida's East Coast, here's four stocks investors should consider as concerns about the virus reach an all-time high
OraSure Technologies (OSUR) was given a government contract to speed the development of its Zika oral test kit late Tuesday.
Shares of the pharmaceutical company were climbing Wednesday on news of a $16.6 million contract awarded.
Shares of Express were tanking in premarket trading after the apparel retailer posted worse-than-expected earnings.
We keep our Two rating but would consider taking profits if it rises above $8.50.
We used market volatility to add a new position this week and add take profits in another holding.
We used market volatility this week to close one position and add to two others.
It was a busy time of earnings reports for the model portfolio, as the market rose for the sixth straight week.
Second-quarter EPS and revenue beat was driven by sales of its HCV test and cost cutting.
OSUR has exceeded the consensus analyst EPS estimate for five straight quarters.